Pinealon

Pinealon is a peptide marketed for cognition, sleep, and brain health, tied to the pineal gland and central nervous system. It's a synthetic three-amino-acid peptide (Glu-Asp-Arg) from the Russian 'Khavinson' bioregulator family, sold outside Russia as a research peptide, most commonly in oral-capsule form. It is not FDA-approved or approved by any major Western regulator, and most of the evidence comes from Russian research that hasn't been independently replicated in large Western human trials.

Pinealon is marketed for cognition and sleep. Russian clinical and research-community reports describe such uses, based on a proposed mechanism in which short peptides directly influence gene expression. That proposed "peptide-DNA interaction" mechanism is contested in mainstream molecular biology, the literature is concentrated within a single research tradition with limited independent replication, and there is no large Western trial — so the evidence should be read as preliminary.

Not FDA approved for any indication. Not approved as a pharmaceutical drug in any major regulatory jurisdiction outside Russia (FDA, EMA, MHRA, TGA, Health Canada). Available in Russia and several Eastern European countries via the Khavinson short-peptide bioregulator framework developed at the St. Petersburg Institute of Bioregulation and Gerontology since the 1970s. Available in Western markets as a research peptide. Not listed in the WADA 2026 Prohibited List (no anabolic, GH-axis, or growth-factor activity attributed to Pinealon). Not-named is not not-prohibited: WADA's S0 (Non-Approved Substances) prohibits at all times any pharmacological substance "with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development)", which describes this compound — so S0 captures it by default and it is off-limits in drug-tested sport. Verified against the local archive `docs/legal/wada-2026-prohibited-list.txt` (S0 clause + full-text search returning no hit) on 2026-09-07. Sister compound to Epitalon; both are Khavinson short peptides associated with pineal gland function.

Pinealon is not FDA-approved and its long-term safety in humans is not established outside the Russian clinical experience; the gene-expression- related mechanism is a theoretical caution in the context of active cancer. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Pinealon is not approved by the FDA or any major Western regulatory agency as a pharmaceutical drug for any indication. Information in this entry is informational, not medical advice. Always confirm dose calculations and consult appropriate professional guidance before any protocol decisions.

⚠️ The Khavinson short-peptide framework is concentrated within a single research tradition with limited independent replication. The bulk of the Pinealon (and broader Khavinson-peptide) literature comes from Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, with co-authors from a relatively small set of collaborating institutions. This is structurally similar to the BPC-157 / Sikiric-lab citation-concentration pattern flagged elsewhere in the library, but more extreme — the Khavinson framework spans approximately 50 years of Russian gerontology research that has produced limited independent replication outside the original research tradition. The proposed mechanism (direct peptide-DNA interaction modulating gene expression in tissue-specific patterns) is theoretically interesting but is not consistent with mainstream pharmacological understanding of how short peptides interact with cells, and the Western primary-source evidence supporting the mechanism is limited. Researchers should be explicit with themselves about the asymmetric evidence base — strong claims rest on a narrow research tradition.

⚠️ Oral bioavailability claims are unusually strong for a tripeptide. Khavinson peptides are characterized by their developers as orally bioavailable due to the small molecular size (3–4 amino acids), permitting passage through the intestinal epithelium with intact biological activity. This claim contradicts general pharmacological understanding — most peptides are degraded by gastric and intestinal proteases before systemic absorption, with very limited fraction reaching circulation intact. The oral bioavailability claim is supported by some published work from the Khavinson group but has not been characterized in mainstream pharmacokinetic studies in the Western literature. The practical implication for researchers: the most-commonly-reported research-community Pinealon administration route is oral capsules at relatively low doses (typically per capsule, 1–2 capsules daily), with the rationale that small peptides retain activity even at low oral bioavailability fractions because the active metabolites (free amino acids in tissue-specific ratios) themselves modulate gene expression. Researchers should hold this rationale loosely — it is theoretically plausible at very low dose levels but is not validated by independent pharmacokinetic studies.

⚠️ Mechanism — "peptide-DNA direct interaction" is a contested framing. The Khavinson framework proposes that short peptides (3–4 amino acids) penetrate cell membranes and interact directly with specific DNA sequences to modulate gene expression in tissue-specific patterns. This proposed mechanism is unusual from a mainstream molecular biology perspective — short peptides are not typical transcription factors and do not have established sequence-specific DNA binding domains comparable to canonical transcription factors. Some published work from the Khavinson group has reported peptide-DNA binding studies; independent replication outside the originating research tradition is limited. The "peptide-DNA direct interaction" framing should be treated as a research-community hypothesis rather than as established pharmacology — it is the dominant framing in Khavinson-peptide research-community materials but is not consistent with mainstream biology textbook treatments.

Pinealon (EDR) is a synthetic tripeptide developed by the Vladimir Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, as part of a research framework that began in the 1970s and has produced approximately a dozen "short peptide bioregulators" over five decades. The framework's design rationale is that specific tripeptide and tetrapeptide sequences extracted from animal organ tissues retain organ-specific biological activity and can be synthesized for clinical use. Pinealon is associated with the pineal gland and central nervous system; Epitalon is also pineal-associated; other Khavinson short peptides target thymus, pancreas, prostate, and other organs.

Khavinson framework — historical context. The Khavinson short-peptide framework emerged from a Russian Soviet-era research tradition that prioritized organ-tissue-extract-based therapeutics over synthetic small molecules. The original methodology involved extracting short peptide fractions from specific animal organs (initially pineal gland for the pineal-associated peptides) and characterizing their biological effects in long-term gerontology studies — multi-year rodent lifespan extension experiments, organ function preservation studies, and human cognitive/longevity protocols in Russian clinical settings. The framework has produced peptides including Epitalon (pineal, AEDG), Pinealon (pineal, EDR), Vilon (thymus, KE), Livagen (thymus, KEDA), Cortagen (cerebral cortex, AEDP), and others. The framework is unusual within the broader peptide-pharmacology landscape in that approximately 50 years of research have produced extensive Russian clinical use without producing FDA, EMA, or other major Western pharmaceutical approval for any compound in the framework. This regulatory pattern is a meaningful signal about the gap between the Khavinson research tradition's claims and the evidence-quality standards required for major Western pharmaceutical approval.

Mechanism — "peptide-DNA direct interaction" framework (Khavinson hypothesis). The Khavinson group proposes that short peptides like Pinealon penetrate cell membranes and interact directly with specific DNA sequences to modulate gene expression in tissue-specific patterns. The proposed mechanism is documented in a number of Khavinson-group publications describing peptide-DNA binding interactions and downstream gene-expression effects.[¹] In this framing, Pinealon (EDR) is hypothesized to bind specific DNA sequences in pineal and CNS cells to upregulate genes involved in neuronal survival, antioxidant defense, and neuroendocrine signaling. The framing is not consistent with mainstream molecular biology understanding of peptide-DNA interactions — short peptides without zinc-finger, leucine-zipper, or other established sequence-specific DNA-binding domains are not typical transcription factors. Independent replication of the Khavinson peptide-DNA binding work outside the originating research tradition is limited. Researchers should treat the Khavinson mechanism framework as a research-community hypothesis rather than as established pharmacology.

Mechanism — alternative framings. Outside the Khavinson hypothesis, alternative mechanism framings for Pinealon's research-community-reported effects include: (1) generic neurotrophic effects from the constituent amino acids (free Glu, Asp, Arg) absorbed after gastric peptide hydrolysis; (2) placebo-effect contribution to subjective reports in research-community use; (3) genuine but mild biological activity via conventional pharmacological pathways (e.g., effects on amino acid pools, mild antioxidant effects). The mechanistic basis for Pinealon's effects, if any, beyond simple amino acid metabolism, is not well-characterized in mainstream pharmacology.

Common research interests. Pinealon's research-community use spans: - Cognitive support and "anti-aging" longevity protocols — the dominant research-community use, paralleling the Russian clinical use for cognitive disorders in older adults. Researchers report subjective improvements in memory, focus, sleep quality, and general cognitive vitality. - Sleep / circadian rhythm support — the pineal-gland association makes Pinealon a research-community choice for sleep and circadian-rhythm protocols, often as an alternative or adjunct to melatonin or sleep-supportive supplements. - Stack with Epitalon for "Khavinson pineal protocol" — the canonical pairing, paralleling the Selank/Semax pairing for the Russian-nootropic cluster. Mechanism rationale: both peptides are pineal-associated; Pinealon's CNS-cognitive effects + Epitalon's telomerase/longevity effects. - Niche neuroprotective applications — research-community interest in Pinealon for general neuroprotection, often stacked with other research peptides.

Regulatory status. Pinealon's regulatory status outside Russia is "research peptide, not approved as a pharmaceutical drug." It is not on the FDA 503A bulks list as either Category 1 or Category 2. Pinealon is not listed in the WADA 2026 Prohibited List[³] — direct text-search of the canonical 2026 WADA pdf returned no matches for "Pinealon", "EDR", or "Glu-Asp-Arg". Not-named is not not-prohibited: WADA's S0 (Non-Approved Substances) prohibits at all times any pharmacological substance "with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development)", which describes this compound — so S0 captures it by default and it is off-limits in drug-tested sport. Verified against the local archive `docs/legal/wada-2026-prohibited-list.txt` (S0 clause + full-text search returning no hit) on 2026-09-07. Pinealon's mechanism (proposed neurotrophic/cognitive effects via the Khavinson framework) does not have anabolic or performance-enhancing activity that would fall under WADA categories. Researchers competing in WADA-tested sport should still confirm against the most recent annual Prohibited List edition before any competitive event.

Commonly reported

• Mild GI symptoms (transient, with oral use)
• Occasional headache (uncommon)
• No reported tolerance, dependence, or withdrawal syndrome
• Long-term safety in Western populations is essentially unknown. No multi-year human safety dataset exists for Pinealon outside the Russian clinical experience.
• Drug interactions are uncharacterized.
• Pregnancy and lactation safety — no data; default to contraindicated.
• Active malignancy — caution; the gene-expression-modulating framing of the Khavinson mechanism is theoretically concerning in the context of cancer (parallel to the GHK-cu cancer caution). The actual clinical relevance at typical doses is uncharacterized.

Pregnancy and lactation: no data; default to contraindicated

Pediatric use: no data outside specific Russian clinical contexts — should not be used in researchers under 18

Active major malignancy or undiagnosed cancer concern — theoretical caution

Active immunosuppressive therapy — caution; Khavinson peptides are sometimes claimed to have immune-modulating effects

Known peptide allergy or hypersensitivity — contraindicated

Regulatory note (US): Pinealon is sold as a research peptide; not on the FDA 503A bulks list.

Regulatory note (WADA): Pinealon is not listed in the 2026 WADA Prohibited List. Not-named is not not-prohibited: WADA's S0 (Non-Approved Substances) prohibits at all times any pharmacological substance "with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development)", which describes this compound — so S0 captures it by default and it is off-limits in drug-tested sport. Verified against the local archive `docs/legal/wada-2026-prohibited-list.txt` (S0 clause + full-text search returning no hit) on 2026-09-07.[³]

Khavinson bioregulator

A class of short peptides from a Russian/Soviet research program proposed to act as tissue-specific regulators; far less studied in Western literature.

Peptide

A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.

Pineal gland

A small gland in the brain that produces melatonin and helps regulate sleep and circadian rhythm.

Western clinical trial

A study run to the evidence standards used by regulators like the FDA (randomized, controlled, peer-reviewed).

1. Khavinson VKh, Lin'kova NS, Tarnovskaya SI, Umnov RS, Elashkina EV, Durnova AO. (2014). Short peptides stimulate serotonin expression in cells of brain cortex. Bulletin of Experimental Biology and Medicine, 157(1):77-80. doi: 10.1007/s10517-014-2496-y.(PMID 24909721)
2. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. (2015). Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Moscow), 80(3):310-22. doi: 10.1134/S0006297915030062.(PMID 25761685)
3. World Anti-Doping Agency. The 2026 Prohibited List, International Standard (effective 1 January 2026). Canonical PDF: wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (local archival copy in `docs/legal/wada-2026-prohibited-list.pdf`). Pinealon is not listed in the 2026 WADA Prohibited List. S0 note (2026-09-07): not-named is confirmed, but this compound has no approval as a medicine anywhere, so WADA's S0 (Non-Approved Substances) captures it by default — the negative listing rules out a named prohibition, not prohibition.

• Epitalon — discussed together in this entry's stacks section
• Selank — discussed together in this entry's stacks section
• Bronchogen — same mechanism class
• Cardiogen — same mechanism class
• Cartalax — same mechanism class
• Chonluten — same mechanism class